Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Anti-VEGF shows long-term potential against neovascular AMD

04 Oct 2020

Treatment with antivascular endothelial growth factor (anti-VEGF), along with regular monitoring, minimizes the risk of long-term vision loss in patients with neovascular age-related macular degeneration (AMD), a recent study has shown.

The study included 149 eyes from 149 neovascular AMD patients (mean age, 74.5±7.8 years) who were on anti-VEGF therapy. Eyes were divided into two groups according to the primary outcome measure of change in visual acuity (VA) over 10 years of treatment: those with gain of ≥10 letters (good visual outcomes) or with loss of ≥15 letters (worse visual outcomes).

At baseline, the mean VA was 59.5±13.1 ETDRS* letters and the average foveal thickness was 298.7±87.9 µm. Fifteen eyes showed evidence of atrophy at enrolment. Patients were followed up for a mean of 3,667.4±15 days, or 10.04 years.

At the final follow-up, the average change in VA in the overall cohort was –2.1±19.9 letters. Good vision, defined as having a final best-corrected VA (BCVA) of 20/40 or better, was recorded in 33.5 percent of the eyes. Most of the eyes (76.5 percent) saw loss of <15 letters from baseline, though 20 eyes became legally blind, with a BCVA of 20/200 or worse.

Thirty-seven eyes (24.8 percent) gained >10 letters, while loss of ≥15 letters was seen in 23.5 percent of the eyes. Notably, a large drop in VA was reported in 16 eyes, which logged a decrease of ≥30 letters from baseline.

“[T]he current study strongly suggests that by 10 years, in patients with neovascular AMD, good VA outcomes can be achieved and maintained with anti-VEGF therapy in clinical practice,” researchers said.

*Early Treatment Diabetic Retinopathy Study

Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.